Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762709 | 0.92 | NAMPT (0.46) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL2762052 | 0.91 | TSHR (0.53) | MEN1KMT2AF2CA2CA1 | |
| SCHEMBL2762157 | 0.89 | CA2 (0.54) | MEN1KMT2AEPHX2CA2CA1 | |
| SCHEMBL2761776 | 0.89 | TP53 (0.47) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL2761968 | 0.88 | TSHR (0.47) | MEN1KMT2AF2CA2CA1 | |
| SCHEMBL2762556 | 0.88 | CA1 (0.48) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL2762034 | 0.87 | CA2 (0.45) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL2762662 | 0.87 | SMN1; SMN2 (0.51) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL2762406 | 0.86 | EPHX2 (0.48) | MEN1KMT2AEPHX2CA2CA1 | |
| SCHEMBL2762573 | 0.86 | CA2 (0.47) | MEN1KMT2ACA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | claimed |
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-2391601-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086177-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | SLC14A1, UTS2R, UROD | MEN1 2878/4885KMT2A 2192/4885PARP14 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.